You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 274 No. 10, September 13, 1995 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorials
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

From Science to Practice

Meta-analyses Using Individual Patient Data Are Needed

Andrew D. Oxman, MD, MSc, FRCPC; Michael J. Clarke, DPhil; Lesley A. Stewart, PhD

JAMA. 1995;274(10):845-846.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In this issue of THE JOURNAL, Jeng et al1 report discrepancies between the results of meta-analyses using aggregate data available from the literature (MAL) and meta-analyses using individual patient data (MAP). This may be seen as further grounds for mistrusting meta-analysis in general2,3 and MAL in particular,4 but before deciding that all meta-analyses are an exercise in "mega-silliness,"5 consider the alternatives.

See also p 830.

The key characteristic of MAPs is the use of individual patient data (IPD). Meta-analyses using aggregate data also can, and frequently do, include unpublished data, so the term IPD meta-analyses is preferable to avoid confusing issues relating to using IPD and issues relating to using unpublished data.

IPD meta-analyses require international cooperation between the individuals and groups who have conducted relevant trials and a considerable amount of time, personnel, and financial resources.6 These global collaborative endeavors have yielded important information . . . [Full Text PDF of this Article]


Author Affiliations

From the Health Services Research Unit, National Institute of Public Health, Oslo, Norway (Dr Oxman); the Clinical Trial Service Unit and Imperial Cancer Research Fund Cancer Studies Unit, University of Oxford (England) (Dr Clarke); and the Medical Research Council Cancer Trials Office, Cambridge, England (Dr Stewart).


Footnotes

Corresponding author: Andrew D. Oxman, MD, MSc, Health Services Research Unit, National Institute of Public Health, Geitmyrsveien 75, 0462 Oslo, Norway.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.